|
Variables
|
EDN3 promoter
|
|---|
| |
Numbera
|
Unmethylated (percentage)
|
Methylated (percentage)
|
P valueb
|
|---|
|
Total
|
128
|
39 (30.5)
|
89 (69.5)
| |
|
Clinicopathological factors
| | | | |
|
Age at diagnosis
| | | | |
|
≤ 59 years
|
64
|
22 (34)
|
42 (66)
|
0.443
|
|
> 59 years
|
64
|
17 (29)
|
47 (71)
| |
|
Tumour sizec
| | | | |
|
pT1
|
44
|
15 (34)
|
29 (66)
|
0.680
|
|
pT2 to pT4
|
72
|
21 (29)
|
51 (71)
| |
|
Lymph node statusc
| | | | |
|
pN0
|
57
|
16 (28)
|
41 (72)
|
0.676
|
|
pN1 to pN3
|
51
|
17 (33)
|
34 (67)
| |
|
Histological grade
| | | | |
|
G1 and G2
|
68
|
18 (26)
|
50 (74)
|
0.310
|
|
G3
|
49
|
18 (37)
|
31 (63)
| |
|
Histological type
| | | | |
|
Ductal
|
103
|
32 (31)
|
71 (69)
|
0.849
|
|
Lobular
|
15
|
5 (33)
|
10 (67)
| |
|
Other
|
6
|
1 (17)
|
5 (83)
| |
|
Immunohistochemistry
| | | | |
|
Oestrogen receptor
| | | | |
|
Negative (IRSd ≤ 2)
|
33
|
11 (33)
|
22 (67)
|
0.655
|
|
Positive (IRS > 2)
|
85
|
24 (28)
|
61 (72)
| |
|
Progesterone receptor
| | | | |
|
Negative (IRSd ≤ 2)
|
33
|
11 (33)
|
22 (67)
|
0.655
|
|
Positive (IRS > 2)
|
85
|
24 (28)
|
61 (72)
| |
- aOnly female patients with primary invasive breast cancer were included. bFisher exact test (two-sided). cAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19]. dImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3.
